Albireo Pharma Inc Stock News

Albireo Pharma (NASDAQ:ALBO) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open.The consensus EPS Estimate is -$1.81 and the consensus Revenue…

Albireo Pharma (ALBO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ: ALBO ), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on March 1, 2022, to provide a business update and review the company''s financial results for the fourth quarter and year ended December 31, 2021. To access the live conference call by phone, dial 877-407-0792 (domestic) or 201-689-8263 (international), and provide the access code 13727211. A live audio webcast will be accessible from the Media & Investors page of Albireo''s website ir.albireopharma.com/ . To ensure a timely connection to the webcast, it is recommended that participants register at least 15 Full story available on Benzinga.com

Decision provides access to the first drug treatment approved in PFIC for patients in England, Wales and Northern Ireland Positive NICE review completed in less than six months post MHRA approval NICE review is first successful clinical & economic benefit assessment of Bylvay completed in Europe Bylvay already submitted for reimbursement in multiple European countries BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ: ALBO ), a rare liver disease company developing novel bile acid modulators, today announced that the National Institute for Health and Care Excellence (NICE) has issued guidance that recommends Bylvay (odevixibat) for the treatment of all types of progressive familial intrahepatic cholestasis (PFIC) in people aged six months and older. Bylvay is a potent, non-systemic ileal bile acid transport inhibitor (IBATi), administered as a once-daily treatment. With this final recommendation under the Highly Specialised Technologies (HST) pathway, Bylvay will be funded for use within 90 days in the National Health Service in England, Wales and Northern Ireland. "It''s incredibly gratifying to see children with PFIC gain access to the first ever non-surgical treatment option for a disease that causes tremendous suffering, in many cases leading to cirrhosis and liver failure within the first 10 years of life," said Richard Thompson, Professor of Molecular Hepatology at King''s College London and principal investigator of PEDFIC 1 & PEDFIC 2 studies. "Odevixibat represents an important advance for patients, allowing us to respond to urgent treatment needs with a drug option that can provide clinically meaningful benefits and the ability to reduce the disease burden for patients and families who otherwise face PEBD surgery or liver transplant." "Children living with PFIC have an incurable devastating disease that causes pruritus which was treated with liver transplantation.

PFIC caregivers reported high impact on mental and physical health, productivity, career prospects, sleep, relationships and finances Study suggests PFIC caregivers'' quality of life may be comparable to that of cystic fibrosis caregivers BOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ: ALBO ), a rare liver disease company developing novel bile acid modulators, today announced the publication of the PICTURE study in Orphanet Journal of Rare Disease . A multinational, retrospective, cross-sectional study, PICTURE evaluated and quantified the impact that progressive familial intrahepatic cholestasis (PFIC) has on caregivers and found a significant caregiver-reported burden on health-related quality of life (HRQoL), impairment of daily activities, reduced sleep, impact on work productivity, career building challenges and relationship strain. The study illustrates for the first time that PFIC levies a substantial burden that extends beyond the individuals with the disease to those caring for them. "PFIC is a devastating diagnosis.

The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021.

After the approval of Odevixibat in the PFIC, Albireo successfully transforms into a commercial company capable of generating profits.

The average of price targets set by Wall Street analysts indicates a potential upside of 183.9% in Albireo Pharma (ALBO). While the effectiveness of this highly sought-after metric is questionable, th

The stock price of Albireo Pharma Inc (NASDAQ: ALBO) increased by 1.55% in the most recent trading session. This is why it happened.

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in p

Wall Street brokerages forecast that Albireo Pharma, Inc. (NASDAQ:ALBO) will post earnings of ($1.39) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Albireo Pharmas earnings, with estimates ranging from ($2.11) to ($0.93). Albireo Pharma posted earnings per share of ($1.30) in the same quarter last year, []

Wedbush reissued their buy rating on shares of Albireo Pharma (NASDAQ:ALBO) in a report released on Monday morning, PriceTargets.com reports. The brokerage currently has a $84.00 price target on the biopharmaceutical companys stock. A number of other equities analysts also recently commented on ALBO. Robert W. Baird restated a buy rating and issued a $72.00 []

Chicago Capital LLC boosted its stake in shares of Albireo Pharma, Inc. (NASDAQ:ALBO) by 17.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 819,738 shares of the biopharmaceutical company’s stock after acquiring an additional 122,502 shares during the period. Chicago Capital LLC’s holdings in Albireo Pharma were worth $25,576,000 as of its most […]

BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the upcoming departure of Pat Horn, M.D., Ph.D., Chief Medical Officer, who will be leaving at the end of the year after almost three and a half years with the Company. Jan Mattsson, Ph.D., Chief Scientific Officer and co-founder of Albireo, will be taking over as the interim head of R&D, leading research and development of early and late-stage assets and programs. As one of the co-founders of the Company with deep experience in drug development and approvals, Dr. Mattsson is primed to lead the R&D organization with his institutional knowledge, vision for the pipeline and products, and ability to deliver against corporate objectives.

Equities analysts forecast that Albireo Pharma, Inc. (NASDAQ:ALBO) will announce $5.08 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Albireo Pharmas earnings, with the lowest sales estimate coming in at $3.58 million and the highest estimate coming in at $5.88 million. Albireo Pharma reported sales []